Iran Hepatitis Network (IHN) is an active non-governmental association with no political and religious interest connecting Iranian and Middle Eastern research centers and researchers active in the field of liver diseases. The following points are achievements of IHN:
1. Hepatitis Monthly Journal: with JCR IF 1.92 and more than 50% contribution of international authors. The journal had significant IF increase in the recent years and became the prominent journal in the region publishing articles on liver disease.
2. Tehran Hepatitis Conference (THC): Is the biannually international conference of viral hepatitis and liver disease. The 6th THC (THC6) was held in 2015 and the meeting had the collaboration of European Association for the Study of the Liver (EASL). The THC7 will be held in September 2017 and hopefully EASL will have the collaboration as the BEST of EASL. The THC tries to attract participants from region to improve the knowledge of Hepatology in Middle East.
3. National and regional seminars on viral hepatitis and liver diseases.
4. National meetings for compilation and approval of treatment guidelines.
5. Workshops to increase the clinical and molecular knowledge of professionals in the field of hepatology.
6. Public awareness activities and campaigns.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close